Farmaforum Partnering Day 2026

23 Sept 2026 | Madrid, Spain

PartnershipUpdated on 14 September 2026

Patent-Pending Nanotechnology Platform for Immune Cell–Tumor Cell Engagement

Profesor Titular Universidad at Grupo de Nanotecnologia Orgánica - UPM

Madrid, Spain

About

We have developed a proprietary, patent-pending nanotechnology platform designed to improve cancer immunotherapy by selectively connecting immune cells with tumor cells.

The platform promotes immune cell–tumor interaction and redirects immune responses toward cancer cells without requiring complex genetic modification of immune cells.

We are seeking clinical and industrial partners with complementary expertise in cancer immunotherapy, cell therapy, preclinical models and translational research. Potential collaborations include joint validation studies, co-development of new therapeutic applications and participation in national and international collaborative R&D projects.

Our goal is to establish strategic partnerships to accelerate preclinical development and explore the application of this technology across different tumor types and immunotherapeutic strategies.

Looking for

  • Development

Organisation

Similar opportunities